Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes

ABSTRACT: Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes

PROVIDER: PRJNA515266 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR8444160_1.fastq.gz	Fastqsanger.gz
	SRR8444160_2.fastq.gz	Fastqsanger.gz
	SRR8444170_1.fastq.gz	Fastqsanger.gz
	SRR8444170_2.fastq.gz	Fastqsanger.gz
	SRR8444180_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 192

Similar Datasets

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-trans retinoic acid in acute myeloid leukemia across subtypes

Project description:Combined treatment with all-trans retinoic acid and GSK2879552 results in synergistic effects on gene expression, cell proliferation, markers of differentiation, and, most importantly, cytotoxicity.

2019-01-16 | GSE125112 | GEO

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

Project description:This SuperSeries is composed of the following subset Series: GSE34672: Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia [Illumina HumanHT-12 gene expression array] GSE34725: Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia [ChIP-Seq] Refer to individual Series

2012-03-14 | E-GEOD-34726 | biostudies-arrayexpress

Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia across subtypes.

Project description:Lysine specific demethylase 1 (LSD1) is a histone modifying enzyme that suppresses gene expression through demethylation of lysine 4 on histone H3. The anti-tumor activity of GSK2879552 and GSK-LSD1, potent, selective irreversible inactivators of LSD1, has previously been described. Inhibition of LSD1 results in a cytostatic growth inhibitory effect in a range of acute myeloid leukemia cell lines. To enhance the therapeutic potential of LSD1 inhibition in this disease setting, a combination of LSD1 inhibition and all-trans retinoic acid was explored. All-trans retinoic acid is currently approved for use in acute promyelocytic leukemia in which it promotes differentiation of abnormal blast cells into normal white blood cells. Combined treatment with all-trans retinoic acid and GSK2879552 results in synergistic effects on cell proliferation, markers of differentiation, and, most importantly, cytotoxicity. Ultimately the combination potential for LSD1 inhibition and ATRA will require validation in acute myeloid leukemia patients, and clinical studies to assess this are currently underway.

| S-EPMC6545850 | biostudies-literature

Proteomic analysis of human eosinophils stimulated with all-trans retinoic acid and IL-5

Project description:Activated eosinophils is a major cell type to be involved in allergic diseases. IL-5 primarily activates eosinophils and prolongs their survival. In contrast, all-trans retinoic acid has regulatory effects in the immune system. The aim of this study is to clarify the role of all-trans retinoic acid in the regulation of human eosinophils.

2025-05-30 | PXD052710 | JPOST Repository

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Project description:The main purpose of this clinical trial is to learn about the good and the bad effects of all trans retinoic acid (ATRA), atezolizumab and bevacizumab as a possible treatment for advanced colorectal patients. Participants will be treated with the following combination of these drugs: 1. ATRA will be given in a pill form to be taken twice a day at home for 7 days starting on day 1 of a cycle. 2. Atezolizumab will be given through a vein in arm or through mediport over 60-90 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW. 3. Bevacizumab will be given through a vein in arm or through mediport over 20-40 minutes every 2 weeks in the outpatient chemotherapy infusion centers at UTSW.

| 70824 | ecrin-mdr-crc

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

Project description:Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

| PRJNA150425 | ENA

RIME against PBX1 protein in P19.6 mouse embryonal carcinoma cells treated for 48 hours with all-trans retinoic acid

Project description:Identification of PBX1 interactors in P19.6 mouse embryonal carcinoma cells treated for 48 hours with all-trans retinoic acid.

2017-04-03 | PXD006158 | Pride

Gene expression changes in mouse neuroepithelial organoids in response to all-trans retinoic acid.

Project description:We describe the transcriptomic changes in neuroepithelial organoids in response to all-trans retinoic acid.

2022-10-01 | GSE214368 | GEO

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

| PRJNA721930 | ENA

All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

Project description:All-Trans-Retinoic Acid Treatment of IDH Mutant Astrocytes

| PRJNA1061109 | ENA